WB: Use at a dilution of 1/500. Predicted molecular weight: 100 kDa. Optimal dilutions/concentrations should be determined by the end user.
Does not cross react with PDE4B1, PDE4B2 and PDE4B4 nor with PDE4A, PDE4C or PDE4D.
Preservative: 0.02% Thimerosal / MerthiolateConstituents: 20% Glycerol, PBS
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.65 mg/ml (Please refer to the vial label for the specific concentration.)
N-terminal and C-terminal peptide unique to PDE4B3 subtype variants.
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Enzymes of the cAMP-dependent phosphodiesterase type 4 (PDE4) family are important in hydrolyzing cAMP produced by G-protein coupled receptor (GPCR) stimulated adenylyl cyclases. Four genes (PDE4A, B, C and D) make up the PDE4 family. cAMP-dependent phosphodiesterase type B (PDE4B) family is consists of 4 known splice variants, PDE4B1, B2, B3 and a novel 66 kDa PDE4B4 protein. One or more subtype variants of PDE4B are ubiquitously present in all mammalian cells. In CNS, all four PDE4B subtype variants are expressed in varying ratios and their activity is regulated in tandem with GPCRs stimulation. Some PDE4B variants are also substrate for PKA-dependent phosphorylation.